Navigation Links
QIAGEN Advances Leadership in Pre-Analytical Solutions for Next-generation Sequencing (NGS) With Launch of 14 New Cancer Gene Panels
Date:7/15/2014

ysis of relevant genes or gene regions in our targeted oncology studies, we found that the pre-validated GeneRead gene panels are robust and have very streamlined workflows. These gene panels are capable of generating sequencing data from the most difficult of tissue samples. The cloud-based bioinformatics resources are very helpful in the interpretation of the data."

QIAGEN's GeneRead technology provides the most cost-effective, time-efficient approach for target enrichment in preparation for NGS runs on any sequencer. Unlike other approaches for sequencers, GeneRead panels use as little as 10 nanograms of starting DNA material per pool. They are compatible with FFPE samples and do not require any specialized instruments. The proprietary algorithms and chemistry provide industry leading coverage (>96% of coding regions), specificity (>90% of reads on target) and uniformity (>90% of bases are covered by at least 20% of the mean coverage depth) for the targeted DNA sequencing. In addition to their quality advantages, QIAGEN gene panels require only three hours to enrich for targets and provide for a substantially reduced time to go from isolated DNA sample to sequencing-ready libraries.

QIAGEN provides a full range of sample technologies, assay panels and library preparation products which today generate substantial revenue and solve important NGS needs in clinical and clinical research applications in particular. QIAGEN also is developing the benchtop GeneReaderTM NGS platform for the same applications. Combined with QIAGEN's existing NGS portfolio, GeneReader is designed to provide a seamless automated workflow from biological sample, through DNA preparation, enrichment, library preparation, sequencing, data analysis and interpretation, to deliver valuable insights into diseases.

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample
'/>"/>

SOURCE Qiagen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exosome Diagnostics and QIAGEN Expand Collaboration to Develop Non-Invasive Biofluid Diagnostic for Lung Cancer
2. QIAGEN Announces Third Co-Development Program for Companion Diagnostics Paired With Lillys Investigational Cancer Compounds
3. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
4. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
5. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
6. WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan
7. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
8. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
9. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
10. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
(Date:9/2/2015)... NJ (PRWEB) , ... September 02, 2015 , ... ... Technical Services Staff members will be attending Pharma Ed Resources upcoming educational ... respected group of industry leading speakers, this timely conference will provide Updates & ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... Project is Aimed at Developing New Screening Methods and Holds Significant, Potential ... ... Killer, - Biomarker Project holds significant potential for ... detect the disease before ...
... in 24 European ... Countries, - Competitors Precluded from Immediate Commercialization of ... ... &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) announces that the,European Patent Office (EPO) granted on ...
... to Aida Pharmaceuticals, ... Inc.,s Product ... (OTC Bulletin Board: AIDA) today announced that it,has signed two ... the leading microbiology research institutes in the People,s,Republic of China, ...
Cached Biology Technology:Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 2Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A team of international molecular scientists, led by a ... which cells communicate change for example their location during ... adjacent cells. The discovery sheds new light on cell ... to combat diseases such as cancer, rheumatoid arthritis and Alzheimer,s ...
... the behaviour of invasive ants in northern Australia, finding ... networks, CSIRO has recognised the outstanding work of some ... in Melbourne. The CSIRO Medals are awarded each year ... contributions to the organisation. Awarded since 1985, the CSIRO ...
... of altruism has long puzzled researchers and has mainly ... now because I expect there to be some long-term ... at the Primate Research Institute (PRI) and the Wildlife ... altruistically help conspecifics, even in the absence of direct ...
Cached Biology News:Milestone discovery in cell behaviors 2CSIRO medal winners 2CSIRO medal winners 3Chimpanzees help each other on request but not voluntarily 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
... ,human IgG subclass 1 100% ,human IgG subclass ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... 0.04% ,human IgG Fab ...
...
Biology Products: